USL311

Overview

USL311 is an orally active CXCR4 inhibitor. USL311 blocks the activity of the CXCR4 receptor. USL311 is applicable to research related to various cancers including breast cancer , bladder cancer , colon cancer , rectal cancer , liver cancer and glioblastoma.

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Bladder Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-114244
• CAS No.: 1373268-67-7
• Molecular Formula: C24H34N6O
• Molecular Weight: 422.57
• Purity: 99.82%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution
• Availability: In-stock

Source

Original product source